Pegah Ebrahimi receives 29,104 Enovix (ENVX) RSUs as director pay

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Ebrahimi Pegah reported acquisition or exercise transactions in this Form 4 filing.

Enovix Corp director Pegah Ebrahimi reported receiving a grant of 29,104 restricted stock units (RSUs), each representing one share of Enovix common stock. The RSUs were granted at $0.00 per share as part of equity compensation, not an open-market purchase.

The RSUs will vest in four equal installments of 25% on September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the company’s 2027 annual stockholders’ meeting, subject to her continuous service as a director. After this award, she holds 102,043 shares of Enovix common stock, including shares underlying these RSUs.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Ebrahimi Pegah

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	29,104	$0.00	--

Holdings After Transaction: Common Stock — 102,043 shares (Direct, null)

Footnotes (1)

1. Reflects shares issuable on the settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on each of September 11, 2026, December 11, 2026, March 11, 2027 and the earlier of (i) June 11, 2027; or (ii) the date of the Issuer's 2027 annual meeting of stockholders (or the date immediately preceding such date if the Reporting Person's service as a director ends at such meeting due to the director's failure to be re-elected or not standing for re-election), subject to the Reporting Person's continuous service through each applicable vesting date. Includes 29,104 shares issuable upon the settlement of RSUs granted to the Reporting Person.

Key Figures

RSUs granted: 29,104 RSUs Grant price: $0.00 per share Holdings after grant: 102,043 shares +2 more

5 metrics

RSUs granted 29,104 RSUs Equity award to director Pegah Ebrahimi on June 11, 2026

Grant price $0.00 per share Price per share for RSU grant

Holdings after grant 102,043 shares Total Enovix common shares held following transaction

First vesting date September 11, 2026 25% of RSUs vest on this date

Final vesting timeframe June 11, 2027 or 2027 meeting Last 25% of RSUs vest at earlier of this date or 2027 meeting

Key Terms

restricted stock units ("RSUs"), contingent right, vesting, continuous service

4 terms

restricted stock units ("RSUs") financial

"Reflects shares issuable on the settlement of restricted stock units ("RSUs") granted to the Reporting Person."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's common stock."

vesting financial

"25% of the RSUs will vest on each of September 11, 2026, December 11, 2026, March 11, 2027 and the earlier of (i) June 11, 2027; or (ii) the date of the Issuer's 2027 annual meeting..."

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

continuous service financial

"subject to the Reporting Person's continuous service through each applicable vesting date."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/15/2026 - 09:31 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ebrahimi Pegah

(Last)

(First)

(Middle)

C/O ENOVIX CORPORATION

3501 W. WARREN AVENUE

(Street)

FREMONT

CALIFORNIA

94538

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Enovix Corp [ ENVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	06/11/2026		A		29,104⁽¹⁾	A	$0	102,043⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. 1. Reflects shares issuable on the settlement of restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents a contingent right to receive one share of the Issuer's common stock. 25% of the RSUs will vest on each of September 11, 2026, December 11, 2026, March 11, 2027 and the earlier of (i) June 11, 2027; or (ii) the date of the Issuer's 2027 annual meeting of stockholders (or the date immediately preceding such date if the Reporting Person's service as a director ends at such meeting due to the director's failure to be re-elected or not standing for re-election), subject to the Reporting Person's continuous service through each applicable vesting date.

2. Includes 29,104 shares issuable upon the settlement of RSUs granted to the Reporting Person.

Remarks:

	/s/ Arthi Chakravarthy, Attorney-in-Fact for Pegah Ebrahimi	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Enovix (ENVX) director Pegah Ebrahimi report on this Form 4?

The Form 4 reports that director Pegah Ebrahimi received a grant of 29,104 restricted stock units from Enovix. These RSUs are part of her equity compensation and each unit represents a contingent right to receive one share of Enovix common stock.

How many Enovix RSUs were granted to Pegah Ebrahimi and at what price?

Pegah Ebrahimi was granted 29,104 restricted stock units of Enovix common stock at a price of $0.00 per share. This indicates a compensatory equity award, not an open-market purchase, with value tied to Enovix’s future share price.

What is the vesting schedule for Pegah Ebrahimi’s 29,104 Enovix RSUs?

The 29,104 Enovix RSUs vest in four 25% tranches on September 11, 2026, December 11, 2026, March 11, 2027, and the earlier of June 11, 2027 or the 2027 annual meeting. Vesting requires her continuous service as a director through each date.

How many Enovix shares does Pegah Ebrahimi hold after this RSU grant?

Following the RSU grant, Pegah Ebrahimi holds 102,043 Enovix common shares in total. This figure includes the 29,104 shares issuable upon settlement of the newly granted restricted stock units disclosed in the Form 4 filing.

Are Pegah Ebrahimi’s Enovix RSUs immediately exercisable or subject to conditions?

The Enovix RSUs are subject to vesting conditions and are not immediately deliverable as shares. Each restricted stock unit converts into one share of common stock only upon vesting, contingent on her continuous service as a director through each vesting date.

Does this Enovix Form 4 involve any open-market buying or selling by Pegah Ebrahimi?

No, the Form 4 reflects a grant or award acquisition of Enovix restricted stock units, coded as transaction type “A.” The price per share is $0.00, meaning it is an equity compensation award rather than an open-market purchase or sale of existing shares.